Plasmablastic lymphoma: An update.
Jenique BaillyNicholas JenkinsDharshnee ChettyZainab MohamedEstelle R VerburghJessica J OpiePublished in: International journal of laboratory hematology (2022)
Plasmablastic lymphoma (PBL) is a highly aggressive B cell non-Hodgkin lymphoma frequently associated with immunosuppression, particularly human immunodeficiency virus (HIV) infection. Although PBL is rare globally, South Africa has a high burden of HIV infection leading to a higher incidence of PBL in the region. Laboratory features in PBL may overlap with plasmablastic myeloma and other large B cell lymphomas with plasmablastic or immunoblastic morphology leading to diagnostic dilemmas. There are, however, pertinent distinguishing laboratory features in PBL such as a plasma cell immunophenotype with MYC overexpression, expression of Epstein-Barr virus-encoded small RNAs and lack of anaplastic lymphoma kinase (ALK) expression. This review aims to provide a summary of current knowledge in PBL, focusing on the epidemiology, pathophysiology, laboratory diagnosis and clinical management.
Keyphrases
- diffuse large b cell lymphoma
- human immunodeficiency virus
- epstein barr virus
- antiretroviral therapy
- poor prognosis
- south africa
- risk factors
- hepatitis c virus
- hiv positive
- hiv infected
- healthcare
- transcription factor
- cell proliferation
- single cell
- binding protein
- hiv aids
- long non coding rna
- cell therapy
- tyrosine kinase
- bone marrow
- protein kinase
- advanced non small cell lung cancer